Basiliximab
- Generic Name
- Basiliximab
- Brand Names
- Simulect
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 179045-86-4
- Unique Ingredient Identifier
- 9927MT646M
- Background
A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cel...
- Indication
For prophylactic treatment of kidney transplant rejection
- Associated Conditions
- Rejection Acute Renal
- Associated Therapies
- -
Basiliximab in Moderate to Severe Ulcerative Colitis
- First Posted Date
- 2007-02-02
- Last Posted Date
- 2008-12-18
- Lead Sponsor
- Cerimon Pharmaceuticals
- Target Recruit Count
- 181
- Registration Number
- NCT00430898
Prospective, Randomized Trial of Basiliximab (Simulect) in the Prophylaxis of High-Risk Keratoplasty Patients
- Conditions
- First Posted Date
- 2006-12-11
- Last Posted Date
- 2006-12-13
- Lead Sponsor
- University Hospital Freiburg
- Registration Number
- NCT00409656
Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy
- Conditions
- Interventions
- First Posted Date
- 2006-09-19
- Last Posted Date
- 2015-02-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 276
- Registration Number
- NCT00378014
- Locations
- 🇨🇭
Novartis Investigative Site, Zurich, Switzerland
A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Novartis
- Target Recruit Count
- 228
- Registration Number
- NCT00369161
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
An Open, Randomized Pilot Study to Evaluate the Use of Basiliximab With an Optimized Cyclosporine Dosing on Renal Function in "de Novo" Liver Transplantation.
- Conditions
- First Posted Date
- 2006-06-22
- Last Posted Date
- 2010-08-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 48
- Registration Number
- NCT00343226
EXTEND Protocol for Transplanted Patient to Evaluate Kidney Function
- Conditions
- First Posted Date
- 2006-03-14
- Last Posted Date
- 2007-04-12
- Lead Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Target Recruit Count
- 50
- Registration Number
- NCT00302497
- Locations
- 🇨🇦
MUHC Royal Victoria Hospital, Montreal, Quebec, Canada
Steroid Free Immunosuppression in Liver Transplantation
- Conditions
- Interventions
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2012-11-19
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 40
- Registration Number
- NCT00296244
- Locations
- 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Safety and Efficacy of Basiliximab in Calcineurin Inhibitor Intolerant Long-term Kidney Transplant Recipients Treated With Mycophenolic Acid and Steroids
- Conditions
- Interventions
- First Posted Date
- 2006-02-01
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 7
- Registration Number
- NCT00284947
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2005-11-09
- Last Posted Date
- 2011-05-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 833
- Registration Number
- NCT00251004
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Efficacy and Safety of Basiliximab in Hepatitis C Virus Positive Patients Undergoing Liver Transplantation
- Conditions
- First Posted Date
- 2005-10-14
- Last Posted Date
- 2010-09-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 194
- Registration Number
- NCT00238901
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.